Lifeline Biotechnologies, Inc. (LLBO) Stock

About Lifeline Biotechnologies, Inc.

Lifeline Biotechnologies, Inc. operates as a medical technology company in the United States. Its technologies focus on prevention, early diagnosis, and quick recovery of various diseases. The company offers First Warning System, a non-invasive, non-compressive, and non-radiogenic device used in assisting the early discovery of breast tissue abnormalities in women. It also provides Mastascope, a hand held endoscope designed to enter the breast nipple via one of its milk ducts, thus permitting the physician to visualize the interior aspects of the breast; and OVASCOPE, an ultra slim endoscope to directly visualize the ovarian surface in the search for cancer. The company also has operations in Europe. Lifeline Biotechnologies, Inc. was incorporated in 1981 and is headquartered in Reno, Nevada.

Lifeline Biotechnologies, Inc. (LLBO) stock trades at $0.00 with a market capitalization of $2.17M. The stock is valued at a price-to-earnings (P/E) ratio of -37.30, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, Lifeline Biotechnologies, Inc. generates a return on equity (ROE) of 0.00%, return on capital employed of 0.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.lbti.co